It is often assumed that tumor rejection is mainly the result of cytotoxic T lymphocytes (CTLs) killing the tumor cells. However, recent studies have demonstrated that the rejection process is not as simple as this. In some models, tumors are rejected in the absence of lytic mechanisms (e.g. perfori
Mathematical modelling of the competition between tumors and immune system considering the role of the antibodies
โ Scribed by M. Kolev
- Publisher
- Elsevier Science
- Year
- 2003
- Tongue
- English
- Weight
- 820 KB
- Volume
- 37
- Category
- Article
- ISSN
- 0895-7177
No coin nor oath required. For personal study only.
โฆ Synopsis
A variety of immune system cells can recognize and destroy the autologous turnor cells. For the realization of the cytotoxic function of the effector cells, their close contact with the surface of the target cells is necessary. Such close contact can be realized not only through direct cell-cell recognition mechanism but also through some adaptor molecules (antibodies) binding with the effector cells and with the target cells. In the presented paper, this mechanism of the so-called humoral immunity is considered and described in a model of cellular tumor dynamics in competition with the immune system. The model is developed with statistical methods analogous to those of the kinetic theory. The model is expressed in terms of a system of integrodifferential equations.
The role of the antibodies is taken into account. A numerical scheme for treating the system is proposed. The results of the computational simulations are presented and compared with some theoretical and experimental data.
๐ SIMILAR VOLUMES
## Abstract This review summarizes some recent clinical immunological approaches with cytokines and/or antibodies for therapy of advanced breast cancer. It considers the recent advances in genetics and molecular tumor biology related to impaired immunosurveillance involving cytokines and growth fac
## Abstract Protection against bacterial and viral pathogens by antibodies has always been thought to end at the cell surface. Once inside the cell, a pathogen was understood to be safe from humoral immunity. However, it has now been found that antibodies can routinely enter cells attached to viral
Clinical studies in patients having been vaccinated with immunogenic glycoproteins suggest that a monoclonal antibody response is important in helping to induce cell mediated tumor destruction. Such a monoclonal response was noted to characterize the reaction to several different immunogenic antigen